World Conference on Lung Cancer (WCLC)

The International Association for the Study of Lung Cancer (IASLC) is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

World Conference on Lung Cancer (WCLC) is the annual conference hosted by the IASLC organization.

Randomized Phase 3 Study of Osimertinib vs Platinum-Pemetrexed for Patients with EGFR T790M-Positive Advanced NSCLC After EGFR-TKI Therapy (AURA3)
WCLC 2016
Osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for use in patients with locally advanced or metastatic EGFR T790M-positive non–small-cell lung cancer (NSCLC) who have progressed on or after EGFR-TKI therapy. Researchers compared the efficacy and safety of osimertinib with platinum-based chemotherapy plus pemetrexed in this patient population. Read More ›
Nivolumab vs Nivolumab with Ipilimumab in Recurrent Small-Cell Lung Cancer (SCLC) (CheckMate 032)
WCLC 2016
Patients with SCLC whose disease progressed during or after initial platinum-based chemotherapy have few treatment options. Nivolumab alone and combined with ipilimumab has demonstrated clinical benefit in multiple tumor types. Researchers presented updated results for the SCLC cohort of the phase 1/2 CheckMate 032 trial. Read More ›
Subgroup Analyses from Randomized Phase 3 Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC (OAK)
WCLC 2016
Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is approved for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. OAK is one of the 2 international, randomized, open-label clinical trials that demonstrated superior efficacy for atezolizumab over docetaxel. Read More ›
First-Line Afatinib versus Gefitinib in EGFR-Mutated Advanced NSCLC: Updated Overall Survival (OS) Analysis of LUX-Lung 7
WCLC 2016
Afatinib, an irreversible ErbB family blocker, and gefitinib, a reversible EGFR tyrosine kinase inhibitor, are approved for first-line treatment of advanced EGFR-mutated non–small-cell lung cancer (NSCLC). Researchers reported updated OS findings from a phase 2b trial (LUX-Lung 7) that compared afatinib versus gefitinib in first-line patients. Read More ›
Efficacy and Safety of Necitumumab Continuation After Triplet Therapy in Patients with EGFR-Expressing NSCLC (SQUIRE)
WCLC 2016
The SQUIRE study demonstrated that the addition of necitumumab to gemcitabine plus cisplatin improved overall survival in patients with metastatic squamous non–small-cell lung cancer (NSCLC). Researchers evaluated the clinical outcomes associated with this triplet regimen in a subset of patients in the SQUIRE trial whose tumors expressed an epidermal growth factor receptor (EGFR). Read More ›
Phase 3 Study of Alectinib vs Crizotinib in ALK-Positive NSCLC (J-ALEX)
WCLC 2016
Use of an ALK inhibitor is standard in patients with ALK-positive non–small-cell lung cancer (NSCLC). In this phase 3 study, researchers compared 2 ALK inhibitors: crizotinib and alectinib. This randomized trial was designed to demonstrate superior progression-free survival for alectinib compared with crizotinib in ALK-inhibitor–naïve ALK-positive NSCLC. Read More ›
Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation and PD-L1–Positive Metastatic NSCLC
WCLC 2016
Abemaciclib, a small-molecule inhibitor of both cyclin-dependent kinase (CDK)4 and CDK6, has demonstrated single-agent activity in patients with solid tumors, including non–small-cell lung cancer (NSCLC). Pembrolizumab, an inhibitor of PD-1, is approved for patients with metastatic PD-L1–positive NSCLC. Researchers studied abemaciclib combined with pembrolizumab in pretreated patients with NSCLC. Read More ›
Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (KEYNOTE-021 Cohort G)
WCLC 2016
Platinum-based chemotherapy with or without bevacizumab is standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) without genetic aberrations. Pembrolizumab has demonstrated activity in PD-L1–positive advanced NSCLC. Cohort G of the phase 1/2 KEYNOTE-021 study compared pembrolizumab + carboplatin and pemetrexed (CP) with CP in patients with treatment-naive advanced nonsquamous NSCLC. Read More ›
Efficacy and Safety of Necitumumab plus Pembrolizumab in Patients Who Relapsed After Chemotherapy for Metastatic Nonsquamous NSCLC
WCLC 2016
Necitumumab, an epidermal growth factor receptor inhibitor, is approved with gemcitabine and cisplatin for previously untreated advanced squamous non–small-cell lung cancer (NSCLC). Nivolumab, a PD-1 inhibitor, is approved for previously untreated NSCLC, as well as relapsed NSCLC, based on PD-L1 expression. This phase 1b study evaluated combination use of these agents. Read More ›
Randomized, Phase 3 Study of First-Line Ceritinib vs Chemotherapy in Patients with ALK-Positive NSCLC (ASCEND-4)
WCLC 2016
Ceritinib is approved for use in patients with advanced ALK-positive non–small-cell lung cancer (NSCLC) who have progressed following treatment with crizotinib. In ASCEND-4, a multicenter randomized trial in previously untreated adult patients, researchers assessed progression-free survival outcomes for ceritinib compared with standard first-line and maintenance chemotherapy. Read More ›

Page 1 of 2

  • 1
  • 2

© Amplity Health. All Rights Reserved. Privacy Policy